Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMV101 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07376642Phase 1Recruiting
- Sponsor
- Immunofoco
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMV101 in B-cell non-Hodgkin lymphoma, sponsored by Immunofoco. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
IMV101
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07376642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376642.